ArticleCardiovascular diabetology2020

Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.

M Arow et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.